Researchers showed that 1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose among patients with renal cell carcinoma.

Most dismissals have been tied to the president's anti-DEI agenda. However, recent reports indicate that workers in non-DEI roles, who DOGE deems affiliated with DEI initiatives, have lost their jobs ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Vertex Pharmaceuticals (NASDAQ: VRTX) and AstraZeneca (NASDAQ: AZN), two of the world's leading drugmakers, missed last ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B ...

Q3 2025 Earnings Call Transcript February 13, 2025 Operator: And good day. Thank you for standing by. Welcome to VistaGen ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

A new study from the University of Gothenburg reveals that blood thinners, commonly prescribed after blood clots in the leg ...

Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...

The quantum computing firm that's looking to redevelop the former U.S. Steel South Works advanced to the final stage of a Department of Defense quantum computing program.

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) ...

Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...